title: The 5-HT1A receptor full agonist, 8-OH-DPAT inhibits ACTH-induced 5-HT2A receptor hyperfunction in rats: involvement of 5-HT1A receptors in the DOI-induced wet-dog shakes in ACTH-treated rats.
abstract: We examined the influence of 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT), a serotonin 1A (5-HT1A) receptor full agonist, on the wet-dog shake response induced by the (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2A receptor agonist, in adrenocorticotropic hormone (ACTH)-treated rats. Chronic ACTH (100 microg/rat, s.c.) treatment for 14 d increased the wet-dog shake response induced DOI. The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.
authors.affiliation: Department of Pharmaceutical Care and Health Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan. ykita@pheasant.pharm.okayama-u.ac.jp
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Kouhei
authors.initials: K
authors.lastname: Kitagawa
authors.forename: Yoshika
authors.initials: Y
authors.lastname: Fujitani
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Shibata
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Araki
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Sendou
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Gomita
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000009:adverse effects / Q000494:pharmacology*; D000324:Adrenocorticotropic Hormone / Q000009:adverse effects / Q000494:pharmacology*; D000662:Amphetamines / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D001831:Body Temperature / Q000187:drug effects; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007035:Hypothermia / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D011187:Posture; D051381:Rats; D017208:Rats, Wistar; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects* / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000494:pharmacology*; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control
chemical_list: D000662:Amphetamines; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D044282:Receptor, Serotonin, 5-HT1A; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D000324:Adrenocorticotropic Hormone; D007650:Ketanserin; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine